AI Article Synopsis
- Paclitaxel-eluting balloons (PEBs) were compared to everolimus drug-eluting stents (DES) for treating coronary stenoses, focusing on 9-month restenosis rates.
- The study was conducted as a randomized trial with plans to enroll 366 patients, but it was halted after only 125 due to higher rates of revascularization in the PEB + bare-metal stent (BMS) group compared to the DES group.
- Results showed significantly higher restenosis rates and revascularization in the PEB + BMS group, indicating that PEBs before BMS implantation are less effective than everolimus DES stents for this condition.
Article Abstract
Background: Paclitaxel-eluting balloons (PEBs) are a promising alternative to drug-eluting stent (DES) in the treatment of coronary stenoses. The aim of our study was to compare the 9-month restenosis rates of a strategy of predilatation with PEB followed by bare-metal CoCr stent (PEB + BMS group) versus implantation of everolimus DES (DES group).
Methods: This randomized, single-center study planned to enroll 366 patients with stable angina (183 patients per arm) undergoing percutaneous coronary intervention of a de novo, native coronary artery stenosis ≤ 15 mm in length. Primary end point, in a noninferiority study design, was 9-month binary angiographic restenosis. A frequency-domain optical coherence tomography substudy investigated the percentage of uncovered stent struts per lesion, the percentage of malapposed/uncovered struts per lesion, and the percentage of net volume obstruction at 9-month follow-up among the first consecutive 30 patients enrolled in the PEB + BMS group.
Results: The study was prematurely halted after enrollment of 125 patients, 59 in the PEB + BMS group and 66 in the DES group, because of excess of ischemia-driven target lesion revascularization in the PEB + BMS group. When all the enrolled patients completed their follow-up, IDLTR rates were 14% in the PEB + BMS versus 2% in DES group (P = .001). Binary restenosis, either in-stent or in-segment, was significantly higher in the PEB + BMS compared with DES group (17% vs 3% [P = .01] and 25% vs 4% [P = .009] respectively). Frequency-domain optical coherence tomography demonstrated important neointimal regrowth in the PEB + BMS group, similar to historical BMS data.
Conclusion: In the treatment of de novo coronary stenosis, a strategy of predilatation with PEB before BMS implantation was significantly inferior to implantation of an everolimus DES stent in terms of 9-month target lesion revascularization. Frequency-domain optical coherence tomography data confirm the lack of efficacy of this strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2013.08.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
Catheter Cardiovasc Interv
February 2019
Department of cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Objectives: To investigate the relative performance of treatment with a paclitaxel-eluting balloon (PEB) compared with an everolimus-eluting stent (EES) for in-stent restenosis (ISR) in patients with diabetes mellitus (DM).
Background: ISR remains a challenge in contemporary clinical practice, particularly in patients with DM.
Methods: In the multicenter randomized DARE trial, patients with BMS or DES ISR were randomized in a 1:1 fashion to treatment with a PEB or an EES.
Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study.
Catheter Cardiovasc Interv
November 2018
Department of Cardioangiology St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Background: The efficacy of paclitaxel-eluting balloon catheters (PEB) and drug-eluting stents for treatment of bare-metal stent restenosis (BMS-ISR) have been demonstrated in several studies with follow-up times of 9 to 12 months; however, the long-term outcomes of ISR treatment are less defined.
Objectives: We aimed to compare the long-term efficacy of PEB and everolimus-eluting stents (EES) for the treatment of BMS-ISR.
Methods: We analyzed 3-year clinical follow-up data from patients included in the TIS randomized clinical study.
Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis.
BMC Cardiovasc Disord
June 2017
Department of Cardioangiology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Pekařská 664/53, Brno, Czech Republic.
Background: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) with iopromide-coated PEB and everolimus-eluting stents (EES) for treating bare metal stent restenosis (BMS-ISR).
Methods: We enrolled 64 patients with 69 BMS-ISR. The control group comprised patients from the iopromide-PEB and EES arms of a previous TIS study.
Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment.
J Thorac Dis
October 2016
Interventional Cardiology, Fatebenefratelli Hospital, Milano, Italy; ; Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Massa, Italy.
The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known as "restenosis". This phenomenon is due to vessel remodeling/recoil in case of no-stent strategy or, in case of stent employ, "neointimal proliferation" that consists in an excessive tissue proliferation in the luminal surface of the stent otherwise by a further new-occurring atherosclerotic process called "neoatherosclerosis". The exact incidence of in-stent restenosis (ISR) is not easy to determine caused by different clinical, angiographic and operative factors.
View Article and Find Full Text PDFTreatment of Small Vessel Disease With the Paclitaxel Drug-Eluting Balloon: 6-Month Angiographic and 1-Year Clinical Outcomes of the Spanish Multicenter Registry.
J Interv Cardiol
October 2015
Interventional Cardiology Unit, Hospital Sant Pau, Barcelone, Spain.
Background: Small vessel disease (SMD) remains a major challenge because of the increased risk of restenosis. We sought to assess the efficacy and safety of a paclitaxel-eluting balloon (PEB) in patients with SMD.
Methods And Results: One-hundred and four patients with native coronary lesions in small vessels treated by using a PEB were included in this prospective multicenter registry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!